Search

Displaying results 2111 - 2120 of 2674 in total
  1. Drug

    Defactinib

    go.drugbank.com/drugs/DB12282
    ApprovedInvestigational

    [L53208,A273943] Defactinib was approved by the US FDA in May 2025 in a co-package alongside [avutometinib] (called Avmapki Fakzynja) for the treatment of recurrent KRAS-mutated low-grade serous ovarian

  2. Target

    Hypoxia-inducible factor 1

    go.drugbank.com/bio_entities/BE0010297
    TargetHumans

    Forms heterodimers with the aryl hydrocarbon receptor (AHR) to mediate the transcriptional response to xenobiotics by binding xenobiotic response elements (XREs) or dioxin response elements (DREs) in target

    Polypeptides: Aryl hydrocarbon receptor nuclear translocatorSynonyms: Dioxin receptor, nuclear translocator
  3. Drug

    AMZ002

    go.drugbank.com/drugs/DB17017
    Investigational

    AMZ002 is a sterile injectable hormone developed as a purified synthetic polypeptide alternative to current FDA-approved epileptic seizure treatments.

  4. Drug

    Gelatin

    go.drugbank.com/drugs/DB11242
    ApprovedInvestigationalVet approvedWithdrawn

    [A32426] Gelatin is generally recognized as safe (GRAS) by the FDA to be a non-hazardous food or food ingredient. … [L2110] The FDA withdrew its approval for the use of all intravenous drug products containing gelatin. Gelatin continues to be approved for other routes of administration.[L43942]

  5. Target

    Translocator protein

    go.drugbank.com/bio_entities/BE0000736
    TargetHumans

    Was initially identified as peripheral-type benzodiazepine receptor; can also bind isoquinoline carboxamides (PubMed:1847678)

    Synonyms: Mitochondrial benzodiazepine receptor, Peripheral-type benzodiazepine receptor
  6. Drug

    Lunacalcipol

    go.drugbank.com/drugs/DB05024
    Investigational

    CTA018 is a member of a new class of vitamin D analogues with a dual mechanism of action, called Vitamin D Signal Amplifiers. This proprietary new drug is both a potent inhibitor of CYP24 (the enzyme responsible for the breakdown of vita...

  7. Target

    Serine/threonine-protein kinase mTOR

    go.drugbank.com/bio_entities/BE0002386
    TargetHumans

    Serine/threonine protein kinase which is a central regulator of cellular metabolism, growth and survival in response to hormones, growth factors, nutrients, energy and stress signals (PubMed:12087098, PubMed:12150925, PubMed:12150926, Pu...

    Synonyms: FRAP
  8. Drug

    Lusutrombopag

    go.drugbank.com/drugs/DB13125
    ApprovedInvestigational

    Lusutrombopag was approved by the FDA on July 31st, 2018 for the same therapeutic indication under the market name Mulpleta. … Lusutrombopag binds to the transmembrane domain of TPOR expressed on megakaryocytes, and causes the proliferation and differentiation of megakaryocytic progenitor cells from hematopoietic stem cells [FDA

    Categories: Thrombopoietin Receptor Agonist
  9. Drug

    Fidaxomicin

    go.drugbank.com/drugs/DB08874
    ApprovedInvestigational

    [A190516] The FDA initially approved fidaxomicin in May 2011 for the treatment of _C. difficile_-associated diarrhea in adult patients over the age of 18. … [A190486] The approved indication of fidaxomicin was expanded by the FDA in January 2020 to include pediatric patients over the age of 6 months in the treatment population.[L11575]

  10. Drug

    Epcoritamab

    go.drugbank.com/drugs/DB16672
    ApprovedInvestigational

    In May 2023, epcoritamab was approved by the FDA under accelerated approval for the treatment of relapsed or refractory DLBCL. … [L49464] In November 2025, epcoritamab in combination with rituximab and lenalidomide was approved by the FDA for adult patients with relapsed or refractory follicular lymphoma.[L54713]